Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q1 FY21 results · Apr–Jun 2020
Astec LifeSciences reported revenue from operations of ₹111.94 crore (up 45.4% from Q1 FY20) and net profit of ₹16.19 crore for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 111.94 | 76.99 | +45.4% | 180.57 | −38.0% |
| Other income | 1.25 | 0.94 | +33.6% | 5.24 | −76.1% |
| Total income | 113.20 | 77.93 | +45.3% | 185.81 | −39.1% |
| Profit before tax | 21.74 | (1.72) | Turned profit | 39.63 | −45.2% |
| Net profit for the period | 16.19 | (1.11) | Turned profit | 31.18 | −48.1% |
| EPS, basic (₹) | 8.27 | (0.57) | Turned profit | 15.94 | −48.1% |
| Net margin (%) | 14.5 | -1.4 | 17.3 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 111.94 | 76.99 | +45.4% | 180.18 | −37.9% |
| Other income | 1.25 | 0.94 | +33.6% | 5.24 | −76.1% |
| Total income | 113.20 | 77.93 | +45.3% | 185.43 | −39.0% |
| Profit before tax | 21.72 | (1.74) | Turned profit | 39.61 | −45.2% |
| Net profit for the period | 16.17 | (1.12) | Turned profit | 31.17 | −48.1% |
| EPS, basic (₹) | 8.26 | (0.57) | Turned profit | 15.94 | −48.2% |
| Net margin (%) | 14.4 | -1.5 | 17.3 |
Consolidated
- Filed with BSE
- 23 Jul 2020, 14:43 IST
- Board meeting
- 22 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jul 2020, 14:43 IST
- Board meeting
- 22 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE